Search results
Added:
2 years ago
HFA 24 - Dr Finn Gustafsson (Rigshospitalet, DK) joined us onsite at the Heart Failure Association Congress to discuss the findings from a subanalysis of the ARIES HeartMate 3 study (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two…
View more
Added:
10 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly…
View more
Added:
1 year ago
ESC HF 25 - Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Maja Cikes (University Hospital Centre Zagreb, HR) for an insightful wrap up of the novel data concerning preventive cardiology that was presented at 2025's Heart Failure Congress.Trials discussed include:REDICAE (00:42)FINEARTS HF (02:27)CRISPR Gene Editing with Nexiguran Ziclumeran (05:53)HELIOS B (07:12)RESHAPE…
View more
Added:
1 month ago
Dr Robert J Mentz (Duke University Medical Center, Durham, NC, US) joins us to discuss decision-making in cardio-kidney-metabolic (CKM) disease, focusing on how to sequence and individualise guideline-directed therapy when heart failure, renal dysfunction and metabolic disease coexist.Dr Mentz examines how competing priorities — decongestion, blood pressure and renal function — shape the order in…
View more
Added:
1 year ago
HFSA 24 - Dr Akshay Desai (Brigham and Women’s Hospital, US) sits down with us to discuss the findings from FINEARTS-HF across the ejection fraction spectrum in heart failure with mildly reduced and preserved ejection fraction.Interview Questions:1. What was the reasoning behind this study? What was the study design and patient population?2. What was the study design and patient population?3…
View more
Added:
2 months ago
HFA Congress 2026 — Dr Ida Arentz Taraldsen (Amager and Hvidovre Hospital, Copenhagen University Hospital, Hvidovre, DK) discusses REDOX-AHF, a prospective, randomised, blinded, multicentre pilot trial evaluating restrictive versus liberal oxygenation targets in patients hospitalised with acute heart failure and pulmonary congestion.Although oxygen therapy is widely used in the acute management…
View more
Added:
1 year ago
ESC Congress 24 – Join Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (The King Fahd Armed Forces Hospital, SA) for an insightful series of wrap-ups from the ESC Congress 2024 in London.Trials covered in detail include:FINEARTS-HFMRAs in Heart FailureSENIOR RITAEARTH-STEMISCOFFAVATARWatch the Day 1 and Day 2 ESC 24 wrap-ups from Dr Alasnag and Dr Al-Shaibi here.Recorded on-site at the ESC Congress…
View more
Added:
3 months ago
ACC.26 - In this expert interview filmed at ACC.26 in New Orleans, Prof. Felipe Martínez discusses how late-breaking heart failure data are reshaping contemporary pharmacological management. The conversation focuses on new spironolactone results, advanced hemodynamic strategies in HFpEF, and the expanding role of cardiometabolic therapies, including GLP‑1 receptor agonists, in optimising outcomes…
View more
Added:
2 months ago
HFA Congress 2026 — Dr Lars Lund (Karolinska Institute and Karolinska University Hospital, Stockholm, SE) joins us to discuss findings from GOAL-HF1, a randomised, double-blind, placebo-controlled phase 1b/2a trial evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF).This first-in-patient study assessed the safety, tolerability and exploratory efficacy of AC01 — a…
View more
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Gerasimos Filippatos and Prof Muthiah Vaduganathan explore the evolving role of non-steroidal MRAs in heart failure management.
View more